AFT sees breakeven in FY19 after narrowing annual loss on Australian sales growth

AFT sees breakeven in FY19 after narrowing annual loss on Australian sales growth
Paul McBeth
By Paul McBeth May 23 (BusinessDesk) - AFT Pharmaceuticals narrowed its 2018 loss and expects to break even in the 2019 financial year as it dials back spending on research and development and lifts sales. The Auckland-based maker of the Maxigesic painkiller reported a loss of $12.7 million, or 13 cents per share, in the 12 months ended March 31, compared to a loss of $18.4 million, or 19 cents, a year earlier. Operating revenue climbed 16 percent to $80.1 million, of which Australian sales jumped 33 percent to $49.2 million due to over t...